Toralizumab
Source: Wikipedia, the free encyclopedia.
Monoclonal antibody
This article is about a drug. For other uses, see IDEC.
CD40 ligand | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
 N Y (what is this?) (verify) | |
Toralizumab (IDEC 131) was a
Hodgkin's disease).[1]
In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.[2]
The drug was developed by
IDEC Pharmaceuticals
Corporation.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab, American Medical Association.
- ISBN 978-0-8493-3790-1.
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
drug article is a stub. You can help Wikipedia by expanding it. |